Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to investigate whether prescribing a 3-day course of antibiotics after Holmium laser enucleation of the prostate (HoLEP) reduces the risk of urinary tract infection. The findings of this trial will have a major impact on clinical practice to either justify the prescription of antibiotics after HoLEP or give urologists more confidence in not prescribing antibiotics prophylactically after HoLEP.


Clinical Trial Description

Systemic antibiotic usage is the primary driver of antimicrobial resistance both in the index patient and the community. Limiting antibiotic use to indicated patients helps reduction of the risks of antimicrobial overuse, which include associated adverse events, development of multidrug resistant (MDR) organism strains, and increased health-related community burden. (1-3) Holmium laser enucleation of the prostate (HoLEP) has been increasingly used as an effective minimally invasive procedure for the management of enlarged prostate. (4) Most guidelines currently recommend the use of single-dose antibiotic prophylaxis prior to all transurethral procedures for the treatment of benign prostatic hyperplasia including HoLEP. (2,3) Although, most surgeons who perform HoLEP usually extend the antibiotics prophylaxis to 3-7 days or more after HoLEP to avoid the incidence of urinary tract infection. Currently no literature that supports the benefit of prescribing antibiotics routinely to all patients after HoLEP. (5, 6) 2. Significance: This clinical trial will provide insight into the benefit of prescribing antibiotics after HoLEP. This study can be practice-changing for urologists who perform HoLEP as it will decrease the prescription of unnecessary antibiotics. This has major implications for antibiotic stewardship in the field of urology. 3. Objectives & Specific Aims: The purpose of this study is to investigate whether prescribing a 3-day course of antibiotics after HoLEP reduces the risk of urinary tract infection. The findings of this trial will have a major impact on clinical practice to either justify the prescription of antibiotics after HoLEP or give urologists more confidence in not prescribing antibiotics prophylactically after HoLEP. The specific aims of this study are: 1. Avoid the possible unnecessary generalized prolonged antibiotic prophylaxis in patients with HoLEP. 2. Identify the patient and procedure factors that increase the incidence of postoperative urinary tract infection. 3. Possible selection of patients who can benefit from prolonged antibiotic prophylaxis. 4. Help changing the urology practice towards more antibiotic stewardship. 4. Methodology: 4.1 Study Design. Study to be multi-institutional, double armed, randomized controlled trial at Baylor Scott and White medical center in Temple, Texas and Albert Einstein Medical Center in Philadelphia. The study will include 100 patients who will have HoLEP in the two centers within almost one year, between March 2022 and March 2023. All patients will receive a single perioperative antibiotics per the American urological association guidelines. Patients will be randomized in to 2 groups: - Group I: Experimental Group (not receiving antibiotics). - Group II: Control Group (receiving three days of antibiotics after surgery) Each center will have a study coordinator (resident and/or fellow) that will be responsible for randomization using the closed envelope technique. 4.2 Procedures/Methods. Each patient's chart in the study will be subjected to analysis of: 1. Preoperative assessment: - Detailed history and physical examination. - Investigations: - Routine laboratory investigations, urine analysis and culture, serum PSA. - IPSS, Q-max, and PVR 2. Operative details: - Operative time, prostate volume - Estimated blood loss - Any intraoperative complications. 3. Postoperative assessment: During early postoperative follow up, the patient will be assessed for: - Irritative voiding symptoms, urinary urgency, urinary frequency, and urinary incontinence. - IPSS, Quality of life (QOL) - Assessment of PVR. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05274672
Study type Interventional
Source Baylor Research Institute
Contact Marawan M. El Tayeb, MD
Phone 854-724-1773
Email marawan.eltayeb@bswhealth.org
Status Not yet recruiting
Phase Phase 4
Start date March 1, 2022
Completion date June 1, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04495699 - Asymptomatic Renal Calculi in Recurrent Urinary Tract Infections
Terminated NCT05254808 - EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care Phase 3
Completed NCT03680612 - Cefepime/AAI101 Phase 2 Study in Hospitalized Adults With cUTI Phase 2
Completed NCT03282006 - Treating Pyelonephritis an Urosepsis With Pivmecillinam Phase 4
Completed NCT03526484 - The Utility of Urinalysis Prior to In-Office Procedures N/A
Completed NCT05397782 - Effects of Flourish on Recurrent Urinary Tract Infection N/A
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03687255 - Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections Phase 3
Recruiting NCT05227937 - Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study
Completed NCT02864420 - Hospitalization at Home: The Acute Care Home Hospital Program for Adults N/A
Completed NCT03131609 - Avoiding Bacterial Contamination of Clean Catch Urine Cultures in Ambulatory Patients in the Emergency Department
Completed NCT01911143 - A Retrospective, Blinded Validation of a Host-response Based Diagnostics N/A
Completed NCT01333254 - A Trial of Different Methods for Bladder Drainage in Hip Surgery Patients N/A
Terminated NCT00594594 - Adjuntive Probiotic Therapy in Treating Urinary Tract Infections in Spinal Cord Injury Phase 1
Completed NCT00216853 - A Study of Vaginal MicroFlora and Immune Profiles of Patients With Recurrent Urinary Tract Infection N/A
Completed NCT00787085 - The Significance of Funguria in Hospitalized Patients N/A
Completed NCT05719753 - The Effectiveness of a Bacteriophobic Coating on Urinary Catheters N/A
Recruiting NCT05415865 - The Effect of Local Anesthetic Solution in the Bladder Prior to Botox Injections in the Bladder Phase 3
Not yet recruiting NCT05880329 - DIagnoSing Care hOme UTI Study
Recruiting NCT04615065 - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine